PT. RICHMOND, Calif., Nov. 14 Transcept Pharmaceuticals,Inc. today announced that Thomas P. Soloway, Senior Vice President and ChiefFinancial Officer, will present at the 19th Annual Piper Jaffray Health CareConference at the Pierre Hotel in New York City on Tuesday, November 27, 2007at 10:30 AM Eastern Time.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical companyderiving significant new patient benefits from proven CNS drugs. Transceptdevelopment projects leverage new understanding of CNS conditions to provideadditional uses and enhanced clinical benefits for existing active agents. Thelead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a lowdose sublingual formulation of zolpidem that is currently in late phase 3clinical trials for the treatment of insomnia in patients who awaken in themiddle of the night and have difficulty returning to sleep. Another productbeing developed by Transcept is TO-2060, a novel, fixed-dose combination ofolanzapine and ondansetron for the treatment of dopamine associatedpsychiatric disorders. TO-2060 is currently the subject of an initial proof ofconcept trial in the treatment of alcohol use disorder. For more information,please visit the company's website at: http://www.transcept.com.Contacts: Transcept Pharmaceuticals, Inc. The Ruth Group Michael Gill, Investors / Media Director of Communications Stephanie Carrington / Jason Rando (510) 215-3575 (646) 536-7017 / 7025 email@example.com firstname.lastname@example.org email@example.com
SOURCE Transcept Pharmaceuticals, Inc.